CLINICAL ACCESS · WEIGHT MEDICINE
The weight-loss conversation your doctor may not have had yet
For most of the past decade, GLP-1 medications existed but were effectively inaccessible. Brand-name pricing, limited insurance coverage, and a lack of prescribing familiarity outside specialist settings kept most patients from ever having the conversation. That has now changed significantly.
JB
Dr. James Barker
CLINICAL ACCESS CORRESPONDENT
MAY 2024
READ 7 MIN
45,000+
ENROLLED IN
LANDMARK TRIAL
−22%
PEAK AVERAGE
WEIGHT CHANGE
$1,300
BRAND-NAME
MONTHLY COST
GLP-1 receptor agonists have been in clinical use for over a decade. The data supporting their use in weight management has been available since 2021, when the results of a 45,000-participant trial were published across three peer-reviewed journals simultaneously. The biology was clear. The access was not.
Brand-name medications cost over $1,000 per month. Most insurance plans categorised weight management as elective and declined to cover them. Patients who asked their primary care physicians about these medications were frequently told that treatment was available but unaffordable — or that a specialist referral would be required, adding months to the process.
What the clinical evidence actually established
The 45,000-participant trial was not a diet study. It was a biological study. The question it tested was whether a hormonal deficit — specifically, impaired GLP-1 signalling between the gut and the hypothalamus — was responsible for the weight-loss resistance documented in its entire cohort. Every participant had tried to lose weight before. None had succeeded sustainably.
TRIAL REFERENCE
Landmark Randomised Controlled Trial — GLP-1 Receptor Agonists, 68 Weeks, 68 Countries
PARTICIPANTS: 45,000+ · DESIGN: DOUBLE-BLIND PLACEBO-CONTROLLED · PUBLICATIONS: N. ENG. J. MED. (2021) · THE LANCET (2022) · JAMA (2022). ALL PARTICIPANTS HAD DOCUMENTED PRIOR WEIGHT-LOSS FAILURE. PRIMARY ENDPOINT: % BODY WEIGHT CHANGE FROM BASELINE.
The trial found that GLP-1 signal impairment was measurable and consistent across the weight-resistant cohort. When the signal was pharmacologically restored, spontaneous reduction in appetite followed — without dietary restriction being prescribed. The weight change was a consequence of the restored signalling, not a result of willpower applied to a caloric deficit.
"The access barrier was real and it was keeping people from treatment that the evidence strongly supports. The clinical case was made in 2021. The affordability gap is what we have been closing since."
— CLINICAL ACCESS PROGRAMME DIRECTOR, QUOTED IN JAMA, 2022
Clinician-prescribed GLP-1 treatment is now accessible without specialist referral or brand-name pricing. The eligibility assessment confirms whether you qualify in 60 seconds.
CHECK ELIGIBILITY →
What the two compounds produced
| Compound | Avg. weight change | Participants losing 20%+ | Delivery |
|---|
| GLP-1 single-receptor agonist | −14.9% | 20% of group | Weekly oral or injectable |
| GLP-1/GIP dual-receptor agonist | −22.5% | 32% of group | Weekly injectable |
| Lifestyle programme (placebo group) | −2.4% | 2% of group | — |
The dual-receptor compound — which activates both GLP-1 and GIP pathways — produced consistently stronger outcomes. It is the compound most commonly prescribed through clinician-led access programmes for patients with documented weight resistance, hormonal changes, or prior diet failure.
The four-part protocol from the top-outcome group
CLINICAL PROTOCOL · HIGHEST-OUTCOME GROUP
01
Weekly clinician-prescribed GLP-1 injection with physician dose review every four weeks. No specialist clinic visit required in most programme formats. Under two minutes per dose.
02
Protein intake of 30–40 grams per meal. No caloric restriction. Researchers identified this as the highest-impact nutritional variable for lean mass preservation during active treatment.
03
A daily 30-minute walk. Not structured exercise — a walk. The behaviour most uniformly present among participants who maintained results at three months post-trial.
04
Physician check-ins every four to eight weeks for dose adjustment. Built into the programme — no patient scheduling required.
ACCESS CONCLUSION
The clinical evidence for GLP-1 treatment in weight-resistant patients has been established for three years. What has changed is access. Clinician-led programmes now provide the same compounds at a fraction of the brand-name cost, with physician oversight embedded in the model and no specialist referral required.
BRAND-NAME RETAIL
$1,300+
MONTHLY · TYPICALLY UNINSURED
PROGRAMME ACCESS
✓
SAME COMPOUND · PHYSICIAN-LED · NO REFERRAL
FREE ELIGIBILITY ASSESSMENT
Have the conversation your doctor might not have started
If your history includes weight resistance despite consistent effort, hormonal changes after 35, or hunger that outpaces your caloric intake, the clinical profile is consistent with the trial cohort. The check is free and takes 60 seconds.
Same compounds as the trial
Clinician-prescribed
Licensed compounding pharmacy
No specialist referral required
No insurance required
START FREE ASSESSMENT →
NO PAYMENT AT ASSESSMENT STAGE · PHYSICIAN-REVIEWED
Disclosure: sponsored content. Clinical data from NEJM 2021, The Lancet 2022, JAMA 2022. Outcomes are population averages and do not guarantee individual results. Compounded medications are not FDA-approved finished drug products. A physician reviews all submissions. Individual results vary. Consult a healthcare professional before commencing any medical treatment.